Search
Acalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalFurthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. … As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules).
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigational[L34650] Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH). … [A18696,L12633] In May 2021, the FDA updated its prescribing information to contraindicate the use of obeticholic acid in patients with PBC and advanced cirrhosis (e.g. those with portal hypertension or
Miltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalThe CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis.
Pemivibart
go.drugbank.com/drugs/DB18720Investigational[L50326] It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.
Amlexanox
go.drugbank.com/drugs/DB01025ApprovedWithdrawnAmlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. Recurrent aphthous ulcer (RAU)...
Zotepine
go.drugbank.com/drugs/DB09225ApprovedWithdrawn[A31857] Zotepine was never approved by the FDA. … [L1082] When the analysis of antipsychotics was retaken in 2016 by the FDA, zotepine did not reach the threshold effect to be further studied.[L1313].
Molnupiravir
go.drugbank.com/drugs/DB15661Investigational[L39050] Molnupiravir was also granted emergency use authorization by the FDA on December 23, 2021; however, it is not yet fully approved.[L39588]
Lunacalcipol
go.drugbank.com/drugs/DB05024InvestigationalCTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vita...
KD7040
go.drugbank.com/drugs/DB05214InvestigationalKD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07. It is being developed by Kalypsys.
Amobarbital
go.drugbank.com/drugs/DB01351ApprovedIllicit(From Martindale, The Extra Pharmacopoeia, 30th ed, p565)